Prostate Cancer Reports
54

Volume 5 Issue 1
January 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Number 1, January


CONTENTS



CASE REPORTS
DIAGNOSIS AND EVALUATION
FOLLOW-UP AND QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOMES
TREATMENT





CASE REPORTS



Wang SC, McCarthy LP, Mehdi S.
Isolated Hepatic Metastasis from Prostate Carcinoma.
Urol Case Rep. 2016 Dec 6;10:51-53.
Source | Abstract | Full text | Similar articles





DIAGNOSIS AND EVALUATION



Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
BJU Int. 2016 Dec 15. doi: 10.1111/bju.13739. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




An H, Tao N, Li J, Guan Y, Wang W, Wang Y, Wang F.
Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
Cell Physiol Biochem. 2016;40(5):1052-1062. Epub 2016 Dec 12.
Source | Abstract | Full text | Similar articles




Bossi A, Mottet N, Blanchard P.
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time?
Eur Urol. 2017 Mar;71(3):349-350. doi: 10.1016/j.eururo.2016.10.051.
Epub 2016 Nov 11.
Source | Abstract | Full text | Similar articles




Couñago F, Recio M, Maldonado A, Del Cerro E, Díaz-Gavela AA, Thuissard IJ, Sanz-Rosa D, Marcos FJ, Olaciregui K, Mateo M, Cerezo L.
Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Cancer Imaging. 2016 Dec 7;16(1):42.
Source | Abstract | Full text | Similar articles




Epstein JI.
Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens.
Eur Urol. 2016 Dec 29. pii: S0302-2838(16)30918-6. doi: 10.1016/j.eururo.2016.12.014. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, Bonekamp D, Kopka K, Eder M, Heusser T, Kachelriess M, Wieczorek K, Sachpekidis C, Flechsig P, Giesel F, Hohenfellner M, Haberkorn U, Schlemmer HP, Dimitrakopoulou-Strauss A.
Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.
Eur J Nucl Med Mol Imaging. 2016 Dec 17. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hansel DE.
The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment.
J Urol. 2017 Feb;197(2S):S140-S141. doi: 10.1016/j.juro.2016.11.028. Epub 2016 Dec 20.
Source | Abstract | Full text | Similar articles




He J, Albertsen PC, Moore D, Rotter D, Demissie K, Lu-Yao G.
Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
Eur Urol. 2016 Dec 7. pii: S0302-2838(16)30883-1. doi: 10.1016/j.eururo.2016.11.031. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR.
Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
Eur Urol. 2016 Dec 9. pii: S0302-2838(16)30884-3. doi: 10.1016/j.eururo.2016.11.032. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Morlacco A, Karnes RJ.
The New Prostate Cancer Grading System in High-risk Disease: A Big Step Forward?
Eur Urol. 2016 Dec 8. pii: S0302-2838(16)30879-X. doi: 10.1016/j.eururo.2016.11.027. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Parker WP, Karnes RJ, Mynderse LA, Lowe VJ, Nathan MA, Kwon ED, Davis BJ.
Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? Eur Urol 2017;71:349-50: C-11 Choline PET/CT and Guideline-directed Care.
Eur Urol. 2017 Mar;71(3):351-352. doi: 10.1016/j.eururo.2016.11.022. Epub 2016 Nov 30.
Source | Abstract | Full text | Similar articles




Stensland KD, Coutinho K, Hobbs AR, Haines L, Collingwood SA, Kwon YS, Hall SJ, Katsigeorgis M, Jazayeri SB, Samadi DB.
Are magnetic resonance imaging undetectable prostate tumours clinically significant? Results of histopathological analyses.
Arab J Urol. 2016 Oct 27;14(4):256-261.
Source | Abstract | Full text | Similar articles




Su HC, Zhu Y, Ling GW, Hu SL, Xu XP, Dai B, Ye DW.
Evaluation of [99]mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Asian J Androl. 2016 Dec 13. doi: 10.4103/1008-682X.192638. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





FOLLOW-UP AND QUALITY OF LIFE



Dahm P, Wilt T.
In prostate cancer, urinary and sexual function were worse with prostatectomy than active monitoring or radiotherapy.
Ann Intern Med. 2016 Dec 20;165(12):JC62. doi: 10.7326/ACPJC-2016-165-12-062.
Source | Abstract | Full text | Similar articles




Johnson ME, Zaorsky NG, Martin JM, Ruth K, Greenberg RE, Uzzo RG, Hayes SB, Smaldone MC, Kutikov A, Viterbo R, Chen DY, Hallman MA, Sobczak ML, Horwitz EM.
Patient reported outcomes among treatment modalities for prostate cancer.
Can J Urol. 2016 Dec;23(6):8535-8545.
Source | Abstract | Full text | Similar articles





INTEGRATIVE MEDICINE



Bernichtein S, Pigat N, Barry Delongchamps N, Boutillon F, Verkarre V, Camparo P, Reyes-Gomez E, Méjean A, Oudard SM, Lepicard EM, Viltard M, Souberbielle JC, Friedlander G, Capiod T, Goffin V.
Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
Cancer Res. 2017 Jan 15;77(2):355-365. doi: 10.1158/0008-5472.CAN-16-0687. Epub 2016 Nov 22.
Source | Abstract | Full text | Similar articles




Fenner A.
Prostate cancer: Calcium promotes cancer; vitamin D decelerates.
Nat Rev Urol. 2017 Feb;14(2):68. doi: 10.1038/nrurol.2016.257. Epub 2016 Dec 6.
Source | Abstract | Full text | Similar articles




Tan P, Zhang C, Wei SY, Tang Z, Gao L, Yang L, Wei Q.
Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review.
Asian J Androl. 2016 Dec 2. doi: 10.4103/1008-682X.190327. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Tsai PH, Cheng CH, Lin CY, Huang YT, Lee LT, Kandaswami CC, Lin YC, Lee KP, Hung CC, Hwang JJ, Ke FC, Chang GD, Lee MT.
Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells.
Anticancer Res. 2016 Dec;36(12):6367-6380.
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Freedland SJ.
Low-risk prostate cancer: to treat or not to treat.
Lancet Oncol. 2016 Dec 19. pii: S1470-2045(16)30651-9. doi: 10.1016/S1470-2045(16)30651-9. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Giri VN, Beebe-Dimmer JL.
Familial prostate cancer.
Semin Oncol. 2016 Oct;43(5):560-565. doi: 10.1053/j.seminoncol.2016.08.001. Epub 2016 Aug 18.
Source | Abstract | Full text | Similar articles




Zhuang L, Johnson MT.
How Precisely Can Prostate Cancer Be Managed?
Int Neurourol J. 2016 Nov;20(Suppl 2):S120-130. Epub 2016 Nov 22.
Source | Abstract | Full text | Similar articles





PROGNOSIS AND OUTCOMES



Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, Meeks JJ, Yang XJ, Paner GP, Eggener SE.
Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.
Eur Urol. 2016 Dec 13. pii: S0302-2838(16)30880-6. doi: 10.1016/j.eururo.2016.11.028. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Aoun F, Albisinni S, Henriet B, Tombal B, Van Velthoven R, Roumeguère T.
Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Scand J Urol. 2017 Feb;51(1):20-26. doi: 10.1080/21681805.2016.1263237.
Epub 2016 Dec 2.
Source | Abstract | Full text | Similar articles




Aragon-Ching JB.
Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer.
J Clin Oncol. 2016 Dec 12:JCO2016703520. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Beauval JB, Ploussard G, Cabarrou B, Roumiguié M, Ouzzane A, Gas J, Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X, Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of the Association of French Urology.
Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
World J Urol. 2016 Dec 16. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Dahm P, Wilt T.
In localized prostate cancer, active monitoring, prostatectomy, and radiotherapy did not differ for 10-y cancer deaths.
Ann Intern Med. 2016 Dec 20;165(12):JC63. doi: 10.7326/ACPJC-2016-165-12-063.
Source | Abstract | Full text | Similar articles




Dalela D, Jindal T, Menon M, Abdollah F.
Improved Survival With Local Treatment of Prostate Cancer in Men With Metastatic Disease: Look Before You Leap.
J Clin Oncol. 2016 Dec 12:JCO2016696617. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL.
Mortality and Androgen-Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
J Urol. 2016 Dec 19. pii: S0022-5347(16)32071-7. doi: 10.1016/j.juro.2016.12.086. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Gulati R, Albertsen PC.
Insights from the PLCO trial about prostate cancer screening.
Cancer. 2017 Feb 15;123(4):546-548. doi: 10.1002/cncr.30472. Epub 2016 Dec 1.
Source | Abstract | Full text | Similar articles




Negishi T, Kuroiwa K, Hori Y, Tomoda T, Uchino H, Tokuda N, Furubayashi N, Nagase K, Iwai H, Nakamura M.
Predictive factors of late biochemical recurrence after radical prostatectomy.
Jpn J Clin Oncol. 2016 Dec 8. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474.
Epub 2016 Dec 1.
Source | Abstract | Full text | Similar articles





TREATMENT



Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell'Oglio P, Moschini M, Suardi N, Dehò F, Montorsi F, Schiavina R, Mottrie A, Briganti A.
Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?
Urol Oncol. 2016 Dec 13. pii: S1078-1439(16)30395-7. doi: 10.1016/j.urolonc.2016.11.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lavery HJ, Cooperberg MR.
Clinically localized prostate cancer in 2017: A review of comparative effectiveness.
Urol Oncol. 2017 Feb;35(2):40-41. doi: 10.1016/j.urolonc.2016.11.013. Epub 2016 Dec 18.
Source | Abstract | Full text | Similar articles




Leapman MS, Carroll PR.
What is the best way not to treat prostate cancer?
Urol Oncol. 2017 Feb;35(2):42-50. doi: 10.1016/j.urolonc.2016.09.003. Epub 2016 Oct 13.
Source | Abstract | Full text | Similar articles




Tyson MD, Penson DF, Resnick MJ.
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer.
Urol Oncol. 2017 Feb;35(2):51-58. doi: 10.1016/j.urolonc.2016.03.021. Epub 2016 Apr 28.
Source | Abstract | Full text | Similar articles




Yang L, Chen Y, Tang Z, Xue W, Qiu S, Tan P, Wei Q.
Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study.
Lancet. 2016 Oct;388 Suppl 1:S85. doi: 10.1016/S0140-6736(16)32012-8.
Source | Abstract | Full text | Similar articles




Wang LL, Wallis CJ, Sathianathen N, Lawrentschuk N, Murphy DG, Nam R, Moon D.
'ProtecTion' from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?
BJU Int. 2016 Dec 8. doi: 10.1111/bju.13734. [Epub ahead of print]
Source | Abstract | Full text | Similar articles